These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 25148777)

  • 21. Development of a Triple-Color Pseudovirion-Based Assay to Detect Neutralizing Antibodies against Human Papillomavirus.
    Nie J; Liu Y; Huang W; Wang Y
    Viruses; 2016 Apr; 8(4):107. PubMed ID: 27120611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Establishment and evaluation of a triple-color human papillomavirus pseudovirion neutralization assay].
    Wei SP; Fan F; Chen J; Liu XL; Yang YR; Wang ZP; Song S; Li ZH; Wei MX; Wang DN; Li SW; Xia NS
    Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Oct; 52(10):1039-1044. PubMed ID: 30392324
    [No Abstract]   [Full Text] [Related]  

  • 23. Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines.
    Faust H; Toft L; Sehr P; Müller M; Bonde J; Forslund O; Østergaard L; Tolstrup M; Dillner J
    Vaccine; 2016 Mar; 34(13):1559-1565. PubMed ID: 26896686
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trial.
    Wu T; Hu YM; Li J; Chu K; Huang SJ; Zhao H; Wang ZZ; Yang CL; Jiang HM; Wang YJ; Lin ZJ; Pan HR; Sheng W; Wei FX; Li SW; Wang Y; Zhu FC; Li CG; Zhang J; Xia NS
    Vaccine; 2015 Jul; 33(32):3940-6. PubMed ID: 26100924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study.
    Wentzensen N; Rodriguez AC; Viscidi R; Herrero R; Hildesheim A; Ghosh A; Morales J; Wacholder S; Guillen D; Alfaro M; Safaeian M; Burk RD; Schiffman M
    J Infect Dis; 2011 Jul; 204(1):94-102. PubMed ID: 21628663
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiplexed serologic assay for nine anogenital human papillomavirus types.
    Opalka D; Matys K; Bojczuk P; Green T; Gesser R; Saah A; Haupt R; Dutko F; Esser MT
    Clin Vaccine Immunol; 2010 May; 17(5):818-27. PubMed ID: 20237197
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Detection of neutralizing antibodies and DNA of human papillomavirus 16, 18 in women aged 18-45 years in Funing, Jiangsu province].
    Liu W; Wei F; Tang J; Yang S; Gao Y; Wang T; Jiang Y; Li M; Hong Y; Chu K; Chen W; Hu Y; Zhu F
    Zhonghua Liu Xing Bing Xue Za Zhi; 2016 Mar; 37(3):406-9. PubMed ID: 27005547
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiplex immunoassay to measure antibody response to nine HPV vaccine types.
    Panicker G; Rajbhandari I; Pathak HN; Brady AM; Unger ER
    J Immunol Methods; 2021 Nov; 498():113136. PubMed ID: 34464605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay.
    Opalka D; Lachman CE; MacMullen SA; Jansen KU; Smith JF; Chirmule N; Esser MT
    Clin Diagn Lab Immunol; 2003 Jan; 10(1):108-15. PubMed ID: 12522048
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validation of a triple-color pseudovirion-based neutralization assay for immunogenicity assessment of a 14-valent recombinant human papillomavirus vaccine.
    Gao S; Zhao D; Feng C; Kou Y; Lu J; Luo C; Li X; Wang Y; Xie L
    J Med Virol; 2024 Aug; 96(8):e29859. PubMed ID: 39145587
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Unveiling the seroprevalence of human papillomavirus in Guangdong, China: Implications for vaccination strategies.
    Hu X; Chen Y; Lin W; Ruan Q; Chen H; Li X; Deng Y; Liang C; Lin H; Zeng L; Sun N; Zhao W; Chen L; Yang Y; Sun L; He J; Sun J
    J Med Virol; 2024 Sep; 96(9):e29910. PubMed ID: 39228341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of systemic and mucosal HPV-specific IgG and IgA antibodies in adolescent girls one and two years after HPV vaccination.
    Scherpenisse M; Mollers M; Schepp RM; Meijer CJ; de Melker HE; Berbers GA; van der Klis FR
    Hum Vaccin Immunother; 2013 Feb; 9(2):314-21. PubMed ID: 23149693
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation between ELISA and pseudovirion-based neutralisation assay for detecting antibodies against human papillomavirus acquired by natural infection or by vaccination.
    Zhao H; Lin ZJ; Huang SJ; Li J; Liu XH; Guo M; Zhang J; Xia NS; Pan HR; Wu T; Li CG
    Hum Vaccin Immunother; 2014; 10(3):740-6. PubMed ID: 24384608
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine.
    Luxembourg A; Brown D; Bouchard C; Giuliano AR; Iversen OE; Joura EA; Penny ME; Restrepo JA; Romaguera J; Maansson R; Moeller E; Ritter M; Chen J
    Hum Vaccin Immunother; 2015; 11(6):1313-22. PubMed ID: 25912208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Four-year persistence of type-specific immunity after quadrivalent human papillomavirus vaccination in HIV-infected children: Effect of a fourth dose of vaccine.
    Levin MJ; Huang S; Moscicki AB; Song LY; Read JS; Meyer WA; Saah AJ; Richardson K; Weinberg A;
    Vaccine; 2017 Mar; 35(13):1712-1720. PubMed ID: 28238631
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of antibody responses to human papillomavirus vaccination as measured by three assays.
    Robbins HA; Kemp TJ; Porras C; Rodriguez AC; Schiffman M; Wacholder S; Gonzalez P; Schiller J; Lowy D; Poncelet S; Esser M; Matys K; Hildesheim A; Pinto LA; Herrero R; Safaeian M
    Front Oncol; 2014 Jan; 3():328. PubMed ID: 24455487
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development and Validation of Two Optimized Multiplexed Serologic Assays for the 9-Valent Human Papillomavirus Vaccine Types.
    Nolan KM; Seaton B; Antonello J; Zhang Y; Cook L; Delfino K; Rubinstein LJ; Cheon K; Group T; Luxembourg A; Dubey S
    mSphere; 2023 Apr; 8(2):e0096221. PubMed ID: 36926984
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation on the persistence of anti-HPV immune responses to the quadrivalent HPV vaccine in Chinese females and males: Up to 3.5 years of follow-up.
    Huang T; Liu Y; Li Y; Liao Y; Shou Q; Zheng M; Liao X; Li R
    Vaccine; 2018 Mar; 36(11):1368-1374. PubMed ID: 29428178
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HPV-specific antibodies in female genital tract secretions captured via first-void urine retain their neutralizing capacity.
    Téblick L; Lipovac M; Molenberghs F; Delputte P; De Vos WH; Vorsters A
    Hum Vaccin Immunother; 2024 Dec; 20(1):2330168. PubMed ID: 38567541
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human papillomavirus (HPV) L1 and L1-L2 virus-like particle-based multiplex assays for measurement of HPV virion antibodies.
    Hernandez BY; Ton T; Shvetsov YB; Goodman MT; Zhu X
    Clin Vaccine Immunol; 2012 Sep; 19(9):1348-52. PubMed ID: 22761294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.